Search Results

1. The cobas® Influenza A/B & RSV Nucleic Acid Test for Use on the cobas® Liat System (cobas® Liat Influenza A/B & RSV) is an automated multiplex real-time RT-PCR assay for the rapid in vitro qualitative detection and discrimination of influenza A virus, influenza B virus and respiratory syncytial virus (RSV) RNA in nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors. The test is intended for use as an aid in the diagnosis and differentiation of influenza B, and RSV in humans and is not intended to detect influenza C.
   Negative results do not preclude influenza virus or RSV infection and should not be used as the sole basis for treatment or other patient management decisions. Conversely, positive results do not ruleout bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Performance characteristics for influenza A were established during the 2013-2014 and the 2014-2015 influenza seasons when influenza A/H3 and A/H1N1 pandemic were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

2. The cobas® Influenza A/B & RSV Quality Control Kit contains External Controls for use with the cobas® Liat Influenza A/B & RSV assay. External Controls are run during the Add cobas® Liat Influenza A/B & RSV Tube Lot procedure. Additional External Controls should be tested in accordance with local, state, federal and/or accrediting organization requirements as applicable.

The cobas Liat Influenza A/B & RSV Nucleic Acid Test for Use on the cobas Liat System ("cobas" Liat Influenza A/B & RSV assay") is a rapid, automated in vitro diagnostic test for the qualitative detection of influenza A, influenza B, and RSV RNA in nasopharyngeal swab (NPS) specimens eluted in viral transport media.

The assay targets a well-conserved region of the matrix gene of influenza A (Inf A target), the non-structural protein gene of influenza B (Inf B target), and the matrix gene of RSV (RSV target). An Internal Process Control (IPC) is also included. The IPC is present to control for adequate processing of the target viruses and to monitor the presence of inhibitors in the sample preparation and RT-PCR.

The assay utilizes a single-use disposable cobas® Liat Tube that holds the sample purification and PCR reagents, and hosts the sample preparation and PCR processes. The cobas Liat Tube uses a flexible tube as a sample vessel. It contains all required unit dose reagents pre-packed in tube segments, separated by peelable seals, in the order of reagent use.

The cobas "Liat System automates and integrates sample purification, nucleic acid amplification, and detection of the target sequence in biological samples. The cobas Liat System performs all assay steps from clinical sample and reports assay result automatically. During the testing process. multiple sample processing actuators of the cobas " Liat System compress the cobas" Liat Tube to selectively release reagents from tube segments, move the sample from one segment to another, and control reaction volume, temperature, and time to conduct sample preparation, nucleic acid extraction, target enrichment, inhibitor removal, nucleic acid elution and real-time PCR. An embedded microprocessor controls and coordinates the actions of these sample processors to perform all required assay processes within the closed cobas Liat Tube.

Positive and negative controls are provided in the cobas® Influenza A/B & RSV Quality Control Kit. The positive control comprises inactivated Influenza B and RSV virus in a dried format. The negative control comprises Universal Transport Media (UTM).

To perform the cobas Liat Influenza A/B & RSV assay, an operator first collects a nasopharyngeal swab and places the swab into UTM. The operator transfers the sample into cobas " Liat Influenza A/B & RSV assay tube using a transfer pipette, and scans the tube barcode to identify the test and the sample barcode to code the sample ID with the assay run on the cobas® Liat System. The cobas® Liat Tube is then inserted into the cobas® Liat System. The system performs all the test steps and outputs interpreted results (e.g. Influenza A Detected, Influenza B Not Detected, RSV Not Detected) in ~20 minutes. A report of the interpreted results can be viewed on the cobas " Liat System's LCD screen, and printed directly through a USB or network connected printer. No reagent preparation or additional steps are required other than adding the sample to the cobas Liat Tube. Because all the reagents are contained within the cobas Liat Tube and no sample or reagent needs to be removed from the tube, crosscontamination between samples is minimized.

The results are interpreted by the cobas Liat System software from measured fluorescent signals and real time curve recognition algorithm. All possible final test results are described below.

Here's a breakdown of the acceptance criteria and study details for the cobas® Liat Influenza A/B & RSV Nucleic Acid Test, based on the provided document:

1. Table of Acceptance Criteria & Reported Device Performance

The document doesn't explicitly lay out "acceptance criteria" in a single, aggregated table with pass/fail marks. Instead, it presents performance data for various analytical and clinical studies. For the clinical studies, it provides percentage agreements and confidence intervals. The "acceptance criteria" can be inferred from the reported performance, implying that these values were considered acceptable by the FDA for substantial equivalence.

Here's a table summarizing the key performance metrics from the study. For acceptance criteria, we'll assume that the reported performance figures met the internal thresholds set by the manufacturer and deemed sufficient by the FDA for 510(k) clearance.

Inferred Acceptance Criteria / Reported Performance for cobas® Liat Influenza A/B & RSV Assay

2. Sample Size Used for the Test Set and Data Provenance

• Clinical Test Set Sample Size:

  • Prospective Specimens: 1,350 nasopharyngeal swab (NPS) specimens.
  • Retrospective Specimens: 292 nasopharyngeal swab (NPS) specimens.
  • Total Clinical Samples: 1,642 specimens.

• Analytical Test Set Sample Size (Reproducibility): Approximately 900 runs (10 panel members × 3 replicates × 2 operators × 5 days × 3 sites).

• Data Provenance:

  • Country of Origin: United States (US). Prospective specimens were collected during the 2013-2014 and 2014-2015 flu seasons.
  • Retrospective/Prospective: The study included both prospective and retrospective clinical specimens. Prospective specimens were collected from patients with signs and symptoms of respiratory infection and tested at 12 CLIA waived healthcare facilities. Retrospective specimens were obtained from two reference laboratories and distributed to 3 of the 12 CLIA waived sites for testing.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

The document states that the cobas Liat Influenza A/B & RSV assay results were compared against an "FDA-cleared laboratory-based multiplexed real-time reverse transcriptase PCR (RT-PCR) test (comparator test)."

• Number of Experts: Not explicitly stated as "experts" for ground truth adjudication in the traditional sense, as it relies on a comparator laboratory test. However, the interpretation of the comparator PCR results would implicitly rely on qualified laboratory personnel.
• Qualifications of Experts: Not detailed. It's inferred that the personnel performing and interpreting the comparator FDA-cleared RT-PCR tests were qualified laboratory technologists/scientists. For discordant results in prospective samples, PCR/sequencing was used as a tie-breaker. This would also imply qualified laboratory personnel.

4. Adjudication Method for the Test Set

• For the primary comparison, the cobas Liat assay results were compared directly against the FDA-cleared laboratory-based multiplexed real-time RT-PCR test (comparator test).
• For discordant results between the cobas Liat and the comparator test in the prospective specimens (specifically, when Liat was positive and comparator negative), PCR/sequencing was used as a "tie-breaker" or confirmatory method. For Influenza A, 41 such specimens were tested, with 18 confirmed positive and 23 negative by PCR/sequencing. For Inf B, 6 such specimens were tested, with 5 confirmed positive and 1 negative. For RSV, 15 such specimens were tested, with 3 confirmed positive and 12 negative.
• For retrospective specimens with discordant results (Liat positive, comparator negative), a similar PCR/sequencing method was used, though with fewer details on the number of confirmed cases (e.g., 1 Inf A sample was negative by PCR/sequencing, all 6 RSV samples were positive).

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance

This document describes the performance of an in vitro diagnostic (IVD) nucleic acid amplification test (NAAT), not an AI-assisted imaging device or a decision support system with human readers. Therefore, an MRMC comparative effectiveness study involving human readers and AI assistance is not applicable to this device.

6. If a Standalone (i.e., Algorithm Only Without Human-in-the-Loop Performance) Was Done

The cobas® Liat system is an automated diagnostic system (sample-to-answer) that performs nucleic acid purification, amplification, and detection, and provides an automated interpretation of the results. The results are reported as "Detected" or "Not Detected" for each virus by the instrument's software. As such, the performance data presented (e.g., clinical sensitivity and specificity) intrinsically represent the "standalone" performance of the algorithm/system, as human interpretation of complex signals (like in radiology) is minimized or absent in the final result determination. The operators (nurses and technologists) are responsible for sample collection, loading, and initiating the test, but the interpretation is automated.

7. The Type of Ground Truth Used

The primary ground truth for the clinical validation was an FDA-cleared laboratory-based multiplexed real-time RT-PCR test (comparator test). For discordant results, PCR/sequencing was used as a confirmatory method to establish a more definitive ground truth.

8. The Sample Size for the Training Set

The document does not specify a separate "training set" in the context of machine learning or AI models. This device is a molecular diagnostic assay (RT-PCR) with predefined chemical reactions and detection logic. Its "development" would involve optimizing reagents, primer/probe design, and reaction conditions, rather than training an algorithm on a distinct dataset. The performance characteristics described are from validation studies, not from a "training" phase.

9. How the Ground Truth for the Training Set Was Established

Given that this is an RT-PCR assay and not an AI/ML device that requires a "training set" with ground truth in the AI context, this question is not applicable. The "ground truth" for developing such an assay would come from extensive analytical characterization against known viral positive and negative samples, including quantified viral loads, verified by traditional virological methods (e.g., cell culture infectivity assays, reference PCR methods).

Ask a specific question about this device

The Liat™ Strep A Assay, performed on the Liat™ Analyzer, is a qualitative in vitro diagnostic test for the detection of Streptococus pyogenes (Group A 8-hemolytic Streptococcus, Strep A) in throat swab specimens from patients with signs and symptoms of pharyngitis.

The Liat™ Strep A Assay utilizes nucleic acid purification and polymerase chain reaction (PCR) technology to detect Streptococcus pyogenes by targeting a segment of the Streptococcus pyogenes genome.

The Liat™ Strep A Assay, performed on the Liat™ Analyzer, is a rapid, automated in vitro diagnostic test for the qualitative detection of Streptococcus pyogenes (Group A B-hemolytic Streptococcus, Strep A) DNA in throat swab specimens in Amies medium.

The Liat™ Strep A Assay targets a well-conserved region of Strep A genome. An Internal Process Control (IPC) is also included. The IPC is present to control for adequate processing of the target bacteria through all steps of the assay process and to monitor the presence of inhibitors in the sample preparation and PCR. The sample-to-result time is ~15 minutes.

The assay utilizes a single-use disposable Liat™ Tube that holds the sample purification and PCR reagents, and hosts the sample preparation and PCR processes. The Liat™ Tube contains all required unit dose reagents pre-packed in tube segments, separated by peelable seals, in the order of reagent use.

The Liat™ Analyzer automates and integrates sample purification, nucleic acid amplification, and detection of the target sequence in biological samples. The Liat™ Analyzer performs all assay steps from clinical sample and reports assay result automatically. During the testing process, multiple sample processing actuators of the analyzer compress the Liat™ Tube to selectively release reagents from tube segments, move the sample from one segment to another, and control reaction volume, temperature, and time to conduct sample preparation, nucleic acid extraction, target enrichment, inhibitor removal, nucleic acid elution and real-time PCR. An embedded microprocessor controls and coordinates the actions of these sample processors to perform all required assay processes within the closed Liat™ Tube.

Positive and negative controls are provided in the Liat™ Strep A Assay Quality Control Kit. The positive control comprises inactivated Strep A bacteria in a dried format. The negative control comprises Amies medium.

To perform the Liat™ Strep A Assay, an operator first collects a throat swab and places the swab into Amies transport medium. The operator transfers the sample into the Liat™ Strep A Assay tube using a transfer pipette, and scans the tube barcode to identify the test and the sample barcode to code the sample ID with the assay run on the Liat™ Analyzer. The Liat™ Tube is then inserted into the Liat™ Analyzer. The analyzer performs all the test steps and outputs interpreted results (e.g. Strep A Detected, Strep A Not Detected) in ~15 minutes. A report of the interpreted results can be viewed on the Liat™ Analyzer's LCD screen, and printed directly through a USB or network connected printer. No reagent preparation or additional steps are required other than adding the sample to the Liat™ Tube. Because all the reagents are contained within the Liat™ assay tube and no sample or reagent needs to be removed from the tube, crosscontamination between samples is minimized.

The results are interpreted by the Liat™ Analyzer software from measured fluorescent signals and real time curve recognition algorithm.

Here's a breakdown of the acceptance criteria and study information for the Liat™ Strep A Assay, based on the provided document:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state pre-defined acceptance criteria for clinical performance, but rather presents the computed clinical performance metrics. For analytical performance, criteria are implied by the results (e.g., 95% detection for LOD, absence of cross-reactivity).

2. Sample Size Used for the Test Set and Data Provenance

• Clinical Test Set Sample Size: 570 throat swab specimens were analyzed for clinical performance. An additional 7 specimens initially yielded invalid/indeterminate/aborted results, bringing the total to 577 specimens processed.
• Data Provenance: The clinical study was conducted at six clinical sites in the United States (geographically distinct regions) between December 2013 and April 2014. This indicates a prospective collection of real-world clinical samples.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The document does not specify the number or qualifications of experts used to establish the ground truth. It states that "Performance characteristics of the assay were determined by comparison to culture and latex agglutination for Strep A typing. Discordant results were investigated using PCR and bi-directional sequencing based on published methods." This implies laboratory personnel with expertise in microbiology, culture techniques, latex agglutination, PCR, and sequencing.

4. Adjudication Method for the Test Set

The adjudication method for the clinical test set was:

• Initial comparison: Liat™ Strep A Assay results vs. culture and latex agglutination.
• Discordant results investigation: PCR and bi-directional sequencing.
  • For the 23 Liat positive, culture negative specimens, all 23 were confirmed Strep A positive by PCR/sequencing.
  • For the 3 Liat negative, culture positive specimens, all 3 were confirmed Strep A positive by PCR/sequencing. (Re-testing with Liat also yielded positive results for these 3).

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done for this device. The Liat™ Strep A Assay is an automated in vitro diagnostic test for the qualitative detection of DNA, not an imaging device requiring human interpretation, so MRMC studies are not applicable in this context. It's a standalone device that provides an automated result.

6. Standalone (Algorithm Only) Performance

Yes, the study presents standalone performance. The Liat™ Strep A Assay is an automated system where the analyzer performs all test steps and outputs interpreted results (e.g., "Strep A Detected," "Strep A Not Detected") directly. The results are interpreted by the Liat™ Analyzer software using measured fluorescent signals and a real-time curve recognition algorithm.

7. Type of Ground Truth Used

The ground truth for the clinical study was established using a combination of methods:

• Microbial Culture: The primary comparative method for detecting Streptococcus pyogenes (Group A ß-hemolytic Streptococcus) in throat swab specimens.
• Latex Agglutination: Used for Strep A typing in conjunction with culture.
• PCR and Bi-directional Sequencing: Used as a reference method to resolve discordant results between the Liat™ assay and the primary culture/latex agglutination method. This serves as a highly specific molecular confirmation.

8. Sample Size for the Training Set

The document does not explicitly mention a separate "training set" or its size. For in vitro diagnostic devices like the Liat™ Strep A Assay, method development and initial algorithm design would typically involve a range of known positive and negative samples, and potentially spiked samples, to establish parameters like cut-offs and curve recognition algorithms.

The analytical performance studies (LOD, reactivity, cross-reactivity, interfering substances, etc.) used various biological and chemical samples to characterize the assay's behavior. For instance, the assay cut-offs were determined through "analysis of a combination of negative clinical samples that were spiked with different strains of S. pyogenes at the LOD target level." This could be considered part of the internal development and tuning process, which might be analogous to a training or development dataset in some contexts, but not typically reported as a formalized "training set" in the same way as machine learning models.

9. How the Ground Truth for the Training Set (or assay development) Was Established

As noted above, a formal "training set" with ground truth establishment is not detailed. However, for the development of cut-offs and algorithms, the ground truth was established by:

• Spiking studies: Negative clinical samples were spiked with known concentrations of different strains of S. pyogenes at target LOD levels. This engineered ground truth allows the system to learn to differentiate true positives from negatives and establish appropriate thresholds (Ct value and endpoint amplitude cut-offs) and curve recognition algorithms using known concentrations of bacteria.
• Controlled experiments: Analytical studies like LOD, reactivity, and cross-reactivity used pre-characterized strains and samples, where the presence or absence of specific microbes and their concentrations were known.

Ask a specific question about this device

The IQuum Liat™ Influenza A/B Assay performed on the Liat™ Analyzer is an automated multiplex real-time RT-PCR assay for the rapid in vitro qualitative detection and discrimination of influenza A virus and influenza B virus RNA in nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors. The test is intended for use as an aid in the differential diagnosis of influenza A and influenza B in humans and is not intended to detect influenza C.

Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions. Conversely, positive results do not rule-out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Performance characteristics for influenza A were established when influenza A/H1 and A/H3 were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

The Liat™ Influenza A/B Assay is a rapid, automated in vitro diagnostic test for the detection and differentiation of Influenza type A and type B viral RNA in nasopharyngeal swab (NPS) specimens in universal transport media (UTM) from patients signs and symptoms of respiratory infection. The assay targets a well-conserved region of the matrix gene of Influenza A viral RNA (Inf A target) and non-structural protein (NS) gene of Influenza B (Inf B target). An Internal Process Control (IPC) is also included. The IPC is present to control for adequate processing of the target viruses and to monitor the presence of inhibitors in the RT-PCR reactions.

The Liat Influenza A/B Assay is performed on the lab-in-a-tube technology platform. The system consists of a disposable Liat Influenza A/B Assay Tube and the Liat™ Analyzer. The Liat™ Tube uses a flexible tube as a sample vessel. It contains all required unit dose reagents prepacked in tube segments, separated by peelable seals, in the order of reagent use. Manipulating a Liat Tube, the Liat Analyzer performs all assay steps from raw sample and report assay result automatically, During the testing process, multiple sample processing actuators of the analyzer compress the Liat Tube to selectively release reagents from tube segments, move the sample from one segment to another, and control reaction volume, temperature and time to conduct sample preparation, nucleic acid extraction, target enrichment, inhibitor removal, nucleic acid elution and real-time RT-PCR. An embedded microprocessor controls and coordinates the actions of these sample processors to perform all required assay processes within the closed Liat Tube. Turnaround time from sample input to result is ~20 minutes.

1. Table of Acceptance Criteria and Reported Device Performance:

The document provided is a 510(k) Summary for the IQuum Liat™ Influenza A/B Assay and Liat™ Analyzer, a diagnostic device. For diagnostic devices like this, "acceptance criteria" are typically defined by performance metrics (e.g., sensitivity, specificity, accuracy) that demonstrate the new device is "substantially equivalent" to a legally marketed predicate device. While explicit numerical acceptance criteria are not always stated directly in the summary, the study's results (performance) serve to demonstrate this equivalence. The key performance indicators presented are clinical agreement (sensitivity and specificity) and analytical performance (limit of detection, reactivity, cross-reactivity, interference, precision, reproducibility).

Here's a table summarizing the reported device performance, which the FDA presumably found acceptable for clearance based on substantial equivalence.

Ask a specific question about this device